Aspirin is an effective means to prevent recurrence and death in patients with vascular disease. However, the extent to which patients are aware of this is not known. The objective of the study was to compare the use and knowledge of prophylactic aspirin between patients on repeat cardiovascular drug prescriptions and their matched controls. A cross-sectional survey of 600 patients was carried out in a group general practice. The subjects included 200 patients on repeat cardiovascular drug prescriptions (vascular group), and two age-sex matched groups: patients on other repeat prescriptions (nonvascular group) and patients not on repeat prescriptions (control group), sampled from the practice register. Use and knowledge of prophylactic aspirin were the main outcome measures. Aspirin knowledge was 72% in the vascular group; 53% in the nonvascular group, and 58% in the control group. Apart from patients who reported possible contra-indications to aspirin, 77% of patients with repeat cardiovascular drug prescriptions reported using aspirin regularly compared with 16% and 9% in the nonvascular and control groups, respectively. Amongst patients on repeat cardiovascular drug prescriptions, aspirin knowledge was the strongest predictor of aspirin use. To conclude, use of prophylactic aspirin in one practice was appropriate and had overcome the usual socio-demographic barriers to preventive activity. However, there were still signi cant numbers not using it. Increased usage in patients with vascular disease could be achieved by improving public knowledge of the bene ts of prophylactic aspirin.
Introduction
Aspirin has become established as an important item in the secondary prevention of mortality and morbidity in people with symptomatic vascular disease (Antiplatelet Trialists' Collaboration, 1994) , and evidence is also emerging of its potential value in asymptomatic high risk groups (Medical Research Council, 1998) .
One potential barrier to the full implementation of a policy for aspirin use in primary care is poor knowledge or con icting attitudes on the part of those patients who might bene t. Most studies awareness should help to drive it high on the agenda and to achieve targets of high coverage. However, for this to happen, it is important that we establish current knowledge and attitudes, in order to inform the design and evaluation of interventions to increase uptake.
We have therefore carried out a survey of use and knowledge about aspirin in different groups of general practice patients.
Methods
The setting was a single urban group general practice in North Staffordshire with a registered list size of 14 000 patients. The design was a crosssectional survey. The practice is part of the North Staffordshire GP Research Network. The network has well validated systems of computerized morbidity recording: each practice uses the Egton Medical Information computer System (EMIS), and the network carries out six month audits of data recording quality in the practices. Included in this, to ensure the validity of using particular drugs to identify speci c medical conditions, is a cross check of medication against Read codes for that condition. This computerized recording therefore allows identi cation of disease groups through both morbidity registers and speci c drug searches. In this case, only medications that would be speci cally used in vascular disease were employed in the searches, for example nitrates in oral or transdermal formulation and Nicorandil. The study population consisted of three groups of patients: · Group 1. 200 patients sampled randomly, using random number tables, from all those patients identi ed as currently using cardio-active drugs on a regular basis, aged between 45-74 years. This procedure was based on the computerized repeat prescription information held in the practice. · Group 2. 200 patients sampled, by age and sex frequency matching to those in Group 1, from all patients with repeat prescriptions for drugs other than cardio-active compounds. Again the computerized repeat prescription system provided the sampling frame for this group. · Group 3. 200 patients, frequency matched by age and sex to those in Group 1, sampled from the age/sex register of the practice, after excluding any patients who were receiving repeat prescriptions.
A postal questionnaire was developed mostly using questions previously tested in earlier surveys from the Centre, from the North Staffordshire Health Authority or from the Of ce of National Statistics (ONS). The rst part concerned general health and demography. Social class was determined from current occupation, or most recent if unemployed or retired, using the Registrar General's classi cation (Of ce of National Statistics, 1991). Employment status (working/not working) was considered separately. Physical activity was assessed by a checklist of activities and the number of hours spent on these activities in total per week. In addition a new question asked subjects whether they felt themselves to be 'at risk' of future coronary events. The second part of the questionnaire focused on current use of aspirin and knowledge about the reasons for its use. Aspirin knowledge was based on a checklist of seven items, which asked about potential bene ts and risks of using aspirin in relation to a range of speci c physical health items, including angina, asthma, stroke, stomach ulcers, heart attack, poor circulation and allergy to aspirin (see Appendix 1). If more than half of the responses in the knowledge section were in agreement with what are regarded as 'correct' answers (tick next to 'Angina', 'Stroke', 'Heart attack', 'Poor circulation' and no tick for 'Asthma', 'Stomach ulcers', 'Allergy to aspirin'), the patient was arbitrarily de ned as having knowledge of aspirin use (a subject ticking 'None of these' was considered as having 'no aspirin knowledge' as less than 50% of the answers would be 'correct'). Subjects suffering from a stomach ulcer, aspirin allergy, anti-coagulation therapy or clotting disorder were recorded as having potential contraindications to aspirin use. Finally, a checklist of potential sources of information about aspirin was included, and patients were asked to indicate whether they had learned anything from each of these sources. The questionnaire was piloted in a sample of practice patients to establish its comprehensibility and the completeness of responses to the individual items. It was then mailed to all subjects selected in the three study groups.
Univariate analysis was based on comparisons of frequencies by chi-square tests. Multivariate logistic regression was used to explore independent associations with aspirin knowledge. All statistical tests were assigned a signi cance level of 0.05, and data analysis was carried out using SPSS version 9.0.
Results
There were 600 questionnaires mailed, 200 to each of the three groups (vascular, nonvascular and controls). Overall 470 questionnaires were returned, a response of 78.3%. Response was highest in the vascular group (86%), lower in the other two groups (nonvascular: 79%, nonprescription controls: 70%).
Differences between the three groups in demographic characteristics, as ascertained by the questionnaire, are summarised in Table 1 . There were more individuals in the vascular group who were no longer working or who were in social class IV or V. As might be expected, the cardiovascular risk pro le was different in the three groups. There was more likely to be a family history of vascular disease reported by those in the vascular group, who also had a higher average body mass index and a lower proportion who took physical activity for more than three hours each week. The largest difference was in the proportions feeling more 'at risk'of a vascular event (85%, 27% and 14% in the vascular, nonvascular and control groups respectively). A total of 105 patients in the vascular group (61%) were using aspirin (see Table 2 ). A small proportion in the other two groups were also using it regularly (13% and 9% in nonvascular and control groups respectively). A predictor of use in these two groups was a reported sense of being at risk of a cardiovascular event. After excluding 84 individuals with one of four potential contraindications to aspirin use, these gures were 77%, 16%, and 9% respectively. A small number, seven individuals, were taking aspirin in the presence of a potential contra-indication. Knowledge of aspirin and its advantages and disadvantages was more evenly spread between the three groups: 72%, 53% and 58% for vascular, nonvascular and controls respectively (see Table  2 ). Knowledge levels were better in all groups for the risks of aspirin use than for the bene ts. Table  3 summarizes the associations of various characteristics with aspirin knowledge. Being on a repeat prescription of a cardiovascular drug, having a positive family history, and eating a 'healthy' diet, were all associated with higher levels of aspirin knowledge, but demographic and socio-economic characteristics were not.
Within the vascular group, a crude analysis illustrates that knowledge of aspirin prophylaxis was the strongest predictor of aspirin use (see Table 4 ). Most information about aspirin use in the vascular group was reported by participants as having been obtained from health professionals, particularly the general practitioner (55%) and the hospital specialist (43%). Within the nonvascular and control groups the media, friends and relatives were reported to be the more important sources of such information.
Discussion
This study found that most subjects in one general practice who were on repeat prescriptions for cardiovascular drugs were also using aspirin regularly. However a substantial number were not doing so, and despite some of them having potential contraindications, it is likely that most could have been using aspirin bene cially. Nationally, in Britain, it is considered that there is under utilisation of aspirin for secondary prevention (McCallum et al., 1997) .
Use of aspirin was higher in this 'vascular' group compared with two other groups of patients, one a group who were receiving repeat prescriptions for noncardiovascular drugs, and the other an age and sex matched sample of the population who were not on repeat prescriptions. The fact of being on a repeat prescription for cardiovascular drugs was more important in predicting aspirin use than demographic or lifestyle characteristics, although in our survey the latter was limited to global measures only rather than speci c validated criterion. This suggests that socio-demographic barriers which have been described in relation to lifestyle approaches to coronary prevention (Fleetwood and Packa, 1991; Osler et al., 1992; Reynes et al., 1993; Nourjah et al., 1994; Winkleby et al., 1994) can be overcome in the case of aspirin prophylaxis. Our de nition of knowledge was arbitrarily de ned without validation against any external measure of knowledge but it appeared that among those who were receiving repeat prescriptions for cardiovascular drugs, knowledge according to our construction was by far the strongest predictor of its use. The largest difference between the vascular group and the two control groups was that 85% of those in the vascular group felt 'at risk' compared with 27% and 14% in the nonvascular and control groups respectively. However those who reported using aspirin in the two control groups were more likely to have feelings of being at risk, and so, even in the absence of a clear cardiovascular indication for aspirin use, perception of risk appears to in uence aspirin use. This re ects evidence from the literature that perceived personal risk in uences health-related behaviours (Mirotznik et al., 1995; Meischke et al., 1999) .
The gure for the proportion of people who reported using aspirin in the nonvascular and control groups has a number of possible implications. Firstly, it can be taken as a potential estimate of 'inappropriate therapy', since those who reported which was likely to have in uenced our study population. Future research might usefully explore further the role that 'feelings of risk' might play in in uencing such behaviour. Response rates were reasonable but the possibility of nonresponse bias must be allowed for in our estimates. In particular it may well be that those who did not respond to the questionnaire in the vascular group (14% of those mailed in group 1) were those who also were not using or were not aware of aspirin use. This would imply that potential for improved use and knowledge is larger than we have estimated. The other potential cause for concern is information bias, in particular the validity of self-reported aspirin use. However we validated this question in 60 patients by (i) test-retest repeatability and (ii) checking whether actual medication use from a tablet count was consistent with self-reported use.
Our general conclusion is that knowledge about aspirin prophylaxis was widespread in this parti-cular general practice population and was linked with appropriate use. Among patients who are receiving treatment for cardiovascular diseases, this knowledge might have been gained as a result of being prescribed or advised to use the drug. However the nding that knowledge was associated with appropriately low levels of aspirin use in the two control groups suggests also it does importantly precede and in uence actual use. Given the signi cant minority of patients with cardiovascular disease who are not on aspirin and who are unaware of its importance, policies directed at improving knowledge in this group might lead to better levels of use and further reductions in cardiovascular disease recurrence and complications.
